Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of leuco-methylthioninium bis(hydromethanesulfonate) in Alzheimer's disease or behavioral variant frontotemporal dementia
2014-002013-37Phase 3Terminated
- Sponsor
- TauRx Therapeutics Ltd
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of hydromethylthionine mesylate in Alzheimer's disease (AD) and frontotemporal dementia (FTD), sponsored by TauRx Therapeutics Ltd. Started Aug 2014; status: terminated.
02
Drugs
hydromethylthionine mesylate
03
Conditions
Alzheimer's disease (AD)frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2014-002013-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002013-37.